Shares of Imperva Inc. (IMPV) rallied 14% in pre-market trading Friday after the company showed improvements in its execution strategy with 3Q results coming in ahead of Wall Street expectations. The data security software provider beat by 18 cents a share, and guided Q4 EPS and revs in-line. Following the company’s earnings results the name was upgraded to ‘Overweight’ from ‘Hold’ from Piper Jaffray. The firm also increased its price target on the stock to $44 from $29. IMPV was also raised to $39 from $34 at BMO Capital Markets.
IMPV shares recently gained $3.94 to $37.00. The stock is down more than 13.34% year-over-year and has lost roughly 32.52% year-to-date. In the past 52 weeks, shares of Redwood Shores, California-based company have traded between a low of $18.40 and a high of $67.12.
Imperva Inc. closed Thursday at $32.48. The name has a total market cap of $860.53M.
Sarepta Therapeutics, Inc. (SRPT) rose around 13% in pre-market trading Friday after the FDA expressed in a statement its willingness to conduct a “rolling review” of Sarepta’s NDA for eteplirsen. FDA said it recognizes the unmet medical need in Duchenne muscular dystrophy (DMD) and the urgency to make new treatments available. The organization also said that it will continue to work with Sarepta in their efforts to provide the data it considers critical to FDA’s ability to review the NDA and reach a decision on approvability.
SRPT shares recently gained $2.37 to $18.10. In the past 52 weeks, shares of Cambridge, Massachusetts-based biopharmaceuticl company have traded between a low of $12.12 and a high of $40.12. Shares are down 59.28% year-over-year and 22.78% year-to-date.
Shares of Aegerion Pharmaceuticals, Inc. (AEGR) are down nearly 32% in early trading, after the company reported fiscal Q3 revenue that missed consensus. The biopharmaceutical firm posted revs of $43.7 million in the period, missing the Street’s $49.1 million forecasts. The company guided FY14 revs below consensus.
Following the earnings report, the name was downgraded to ‘Neutral’ from ‘Overweight’, and to ‘Hold’ from ‘Buy’ at JP Morgan (JPM) and Deutsche Bank (DB), respectively.
Aegerion Pharmaceuticals shares currently have a PEG and forward P/E ratio of -0.03 and 21.38, respectively. Price/sales for the same period is 9.74 while EPS is ($1.76). Currently there are 7 analysts that rate AEGR a ‘Buy’ ; 1 rates it a ‘Hold’ and 1 rates it a ‘Sell’. AEGR has a median Wall Street price target of $48.00 with a high target of $107.00.
In the past 52 weeks, shares of Cambridge, Massachusetts-based biopharmaceutical company have traded between a low of $26.25 and a high of $85.34 and are now at $23.10. Shares are down 59.87% in the past 12 months, and 51.79% year-to-date.
Shares of Taser International Inc. (TASR) were downgraded to ‘Sell’ from ‘Fair Value’ by CRT Capital on Friday. The firm also set its 12-month base case estimate to $12. CRT analysts attributed the downgrade to the fact that despite the company’s solid Q3 results, the revenue pull forward indicates Q4 will likely be week and order follow-through should be down after the Ferguson shooting in the summer.
Taser Int’l, currently valued at $929.83M, has a median Wall Street price target of $18.00 with a high target of $19.50.
In the past 52 weeks, shares of the electrical weapons maker have traded between a low of $10.46 and a high of $20.83 with the 50-day MA and 200-day MA located at $15.73 and $14.40 levels, respectively. Additionally, shares of TASR trade at a P/E ratio of 1.64 and have a Relative Strength Index (RSI) and MACD indicator of 70.21 and +1.52, respectively.
TASR currently prints a one year loss of about 1.50%, and a year-to-date return of around 11.46%.
Barrett Business Services (BBSI) – The provider of business management solutions today announced that its board of directors has approved an increase in the company’s regular quarterly cash dividend, raising it from $0.18 to $0.22 per share.
The cash dividend for the current quarter will be paid on December 5, 2014 to all stockholders of record as of November 21, 2014.
Barrett Business Services Inc. gained $1.19 to $21.93 in morning trading today. Approximately 190,798 shares have already changed hands, compared to the stock’s average daily volume of 217,052 shares.
On valuation-measures, shares of Barrett Business Services have a forward P/E of 6.68. P/E to growth ratio is (5.06), while t-12 profit margin is (4.72%). EPS registers at ($3.98). The company has a market cap of $157.39M and a median Wall Street price target of $77.50 with a high target of $80.00.
BBSI currently prints a one year loss of about 75.58%, and a year-to-date loss of around 77.42%.